A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses

References

• Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R. A novel Coronavirus from patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):1–9. doi:10.1056/NEJMoa2001017.
   PubMed Web of Science ®Google Scholar
• Al-Awwal N, Dweik F, Mahdi S, El-Dweik M, Anderson SH. A review of SARS-CoV-2 disease (COVID-19): pandemic in our time. Pathogens. 2022;11(3):368.
   Google Scholar
• Fontanet A, Autran B, Lina B, Kieny MP, Karim SA. Sridhar D. Lancet. 2021;397(10278):952–954. doi:10.1016/S0140-6736(21)00370-6.
   PubMed Web of Science ®Google Scholar
• Nohynek H, Wilder-Smith A. Does the world still need new Covid-19 vaccines? N Engl J Med. 2022;386(22):2140–2142. doi:10.1056/NEJMe2204695.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;383(20):1920–1931. doi:10.1056/NEJMoa2022483.
   PubMed Web of Science ®Google Scholar
• Baden LR, Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck JR, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R. Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley P, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA. Safety and immunogenicity of the ChAdox1 nCov-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478. doi:10.1016/S0140-6736(20)31604-4.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE. Safety and efficacy of the ChAdox1 nCov-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. doi:10.1016/S0140-6736(20)32661-1.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, de Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I. Interim results of a phase 1–2a Trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835. doi:10.1056/NEJMoa2034201.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020;383(24):2320–2332. doi:10.1056/NEJMoa2026920.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887–897. doi:10.1016/S0140-6736(20)31866-3.
   PubMed Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. doi:10.1016/S0140-6736(21)00234-8.
   PubMed Web of Science ®Google Scholar
• Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J. Safety and efficacy of NVX-CoV2373 COVID-19 vaccine. N Engl J Med. 2021;385(13):1172–1183. doi:10.1056/NEJMoa2107659.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, Han W, Chen Z, Tang R, Yin W. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192. doi:10.1016/S1473-3099(20)30843-4.
   PubMed Web of Science ®Google Scholar
• Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV — a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236. doi:10.1038/nrmicro2090.
   PubMed Web of Science ®Google Scholar
• Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W. COVID-19, an emerging coronavirus infection: Advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vacc Immunotherapeut. 2020;16(6):1232–1238. doi:10.1080/21645515.2020.1735227.
   PubMed Web of Science ®Google Scholar
• Yang M, Li CK, Li K, Hon KLE, Ng MHL, Chan PKS, Fok TF. Hematological findings in SARS patients and possible mechanisms (review). Int J Mol Med. 2004;14:311–315.
   PubMed Web of Science ®Google Scholar
• Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 Coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254. doi:10.3390/v12030254.
   PubMed Web of Science ®Google Scholar
• United States Centers for Disease Control on line COVID Data Tracker, 2022.
   Google Scholar
• Greenwood B. The contribution of vaccination to global health: Past, present and future. Philos Trans R Soc B: Biol Sci. 2014;369(1645):20130433. doi:10.1098/rstb.2013.0433.
   PubMed Web of Science ®Google Scholar
• Riedel S. Edward Jenner and the history of smallpox and vaccination. Proceedings (Baylor University, Medical Center). 2005;18(1):21–25. doi:10.1080/08998280.2005.11928028.
   PubMedGoogle Scholar
• Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G. Effectiveness of COVID-19 vaccines against the B.1.617.2 (delta) variant. N Engl J Med. 2021;385(7):585–594. doi:10.1056/NEJMoa2108891.
   PubMed Web of Science ®Google Scholar
• Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall M, Groves N, O’Connell A-M. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386(16):1532–1546. doi:10.1056/NEJMoa2119451.
   PubMed Web of Science ®Google Scholar
• Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses. 2021;149:110538. doi:10.1016/j.mehy.2021.110538.
   PubMed Web of Science ®Google Scholar
• Pulendran B, Ahmed R. Translating innate immunity into immunological memory: implications for vaccine development. Cell. 2006;124(4):849–863. doi:10.1016/j.cell.2006.02.019.
   PubMed Web of Science ®Google Scholar
• Cyster JG, Allen CDC. B cell responses: cell interaction dynamics and decisions. Cell. 2019;177(3):524–540. doi:10.1016/j.cell.2019.03.016.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J, Mellman I. Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010;33(4):464–478. doi:10.1016/j.immuni.2010.10.007.
   PubMed Web of Science ®Google Scholar
• Ueno H, Schmitt N, Palucka AK, Banchereau J. Dendritic cells and humoral immunity in humans. Immunology & Cell Biology. 2010;88(4):376–380. doi:10.1038/icb.2010.28.
   PubMed Web of Science ®Google Scholar
• Schön E, Harandi AM, Nordström I, Holmgren J, Eriksson K. Dendritic cell vaccination protects mice against lethality caused by genital herpes simplex virus type 2 infection. J Reprod Immunol. 2001;50(2):87–104. doi:10.1016/S0165-0378(00)00094-2.
   PubMed Web of Science ®Google Scholar
• Ghasemi M, Erturk M, Buruk K, Sonmez M. Induction of potent protection against acute and latent herpes simplex virus infection in mice vaccinated with dendritic cells. Cytotherapy. 2013;15(3):352–361. doi:10.1016/j.jcyt.2012.11.012.
   PubMed Web of Science ®Google Scholar
• Konduri V, Decker WK, Halpert MM, Gilbert B, Safdar A. Modeling dendritic cell vaccination for influenza prophylaxis: Potential applications for niche populations. J Infect Dis. 2013;207(11):1764–1772. doi:10.1093/infdis/jit087.
   PubMed Web of Science ®Google Scholar
• Decker WK, Safdar A. Dendritic cell vaccines for the immunocompromised patient: Prevention of influenza virus infection. Expert Rev Vaccines. 2010;9(7):721–730. doi:10.1586/erv.10.68.
   PubMed Web of Science ®Google Scholar
• Lu W, Arraes LC, Ferreira WT, Andrieu J-M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10(12):1359–1365. doi:10.1038/nm1147.
   PubMed Web of Science ®Google Scholar
• García F, Climent N, Assoumou L, Gil C, González N, Alcamí J, León A, Romeu J, Dalmau J, Martínez-Picado J. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J Infect Dis. 2011;203(4):473–478. doi:10.1093/infdis/jiq077.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, de Leon C, Mayorga C, Cornforth AN, Allen K. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm. 2009;24(3):311–319. doi:10.1089/cbr.2008.0599.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Depriest C, McClay EF, Amatruda TT, de Leon C, Ellis RE, Mayorga C, Carbonell D, Cubellis JM. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother. 2012;35(8):641–649. doi:10.1097/CJI.0b013e31826f79c8.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Cornforth AN, Nistor GI, McClay EF, Amatruda TT, Depriest C. Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses. J Immunotherapy Cancer. 2018;6(1):19. doi:10.1186/s40425-018-0330-1.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Depriest C. Dendritic cell vaccines presenting autologous tumor antigens from self-renewing cancer cells in metastatic renal cell carcinoma. J Explor Res Pharmacol. 2018;3(4):93–101. doi:10.14218/JERP.2018.00012.
   Google Scholar
• Wang X, Bayer ME, Chen X, Fredrickson C, Cornforth AN, Liang G, Cannon J, He J, Fu Q, Liu J. Phase I trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma. J Surg Oncol. 2015;111(7):862–867. doi:10.1002/jso.23897.
   PubMed Web of Science ®Google Scholar
• Colombo BM, Lacave R, Pioche-Durieu C, Masurier C, Lemoine FM, Guigon M, Klatzmannn D. Cellular but not humoral immune responses generated by vaccination with dendritic cells protect mice against leukaemia. Immunology. 2000;99(1):8–15. doi:10.1046/j.1365-2567.2000.00933.x.
   PubMed Web of Science ®Google Scholar
• Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med. 2000;191(10):1699–1708. doi:10.1084/jem.191.10.1699.
   PubMed Web of Science ®Google Scholar
• Nistor GI, Dillman RO. Cytokine network analysis of immune responses before and after autologous dendritic cell and tumor cell vaccine immunotherapies in a randomized trial. J Transl Med. 2020;18(1):176. doi:10.1186/s12967-020-02328-6.
   PubMed Web of Science ®Google Scholar
• Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, Baxter AE, Herati RS, Oldridge DA, Gouma S. Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination. Immunity. 2021;54(9):2133–2142. doi:10.1016/j.immuni.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Moss P. The T cell immune response against SARS-CoV-2. Nat Immunol. 2022;23(2):186–193. doi:10.1038/s41590-021-01122-w.
   PubMed Web of Science ®Google Scholar
• Dillman RO. A novel vaccine for the novel corona virus. Am J Biomed Sci Res. 2020;11(3):225–226. doi:10.34297/AJBSR.2020.11.001631.
   Google Scholar
• Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDcap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi:10.1016/j.jbi.2008.08.010.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422. doi:10.1056/NEJMoa1001294.
   PubMed Web of Science ®Google Scholar